関崎 知紀 (セキザキ トモノリ)

北海道大学病院 内科 糖尿病・内分泌内科特任助教

研究者基本情報

■ URL
researchmap URLホームページURL■ ID 各種
J-Global ID

研究活動情報

■ 論文
  • Neuromedin B receptor as a potential therapeutic target for corticotroph adenomas
    Tomonori Sekizaki; Hiraku Kameda; Akinobu Nakamura; Saki Kuwabara; Hiroshi Nomoto; Kyu Yong Cho; Yukitomo Ishi; Hiroaki Motegi; Hideaki Miyoshi; Tatsuya Atsumi
    Pituitary, 26, 5, 597, 610, Springer Science and Business Media LLC, 2023年08月29日, [査読有り], [筆頭著者]
    英語, 研究論文(学術雑誌)
  • Dipeptidyl peptidase‐4 inhibitor might exacerbate Graves’ disease: A multicenter observational case–control study
    Tomonori Sekizaki; Hiraku Kameda; Hiroshi Nomoto; Kyu Yong Cho; Akinobu Nakamura; Kiyohiko Takahashi; Arina Miyoshi; Norio Wada; Jun Takeuchi; So Nagai; Hideaki Miyoshi; Tatsuya Atsumi
    Journal of Diabetes Investigation, 12, 11, 1978, 1982, Wiley, 2021年06月16日, [査読有り], [筆頭著者]
    英語, 研究論文(学術雑誌), Abstract

    Dipeptidyl peptidase‐4 (DPP‐4), namely CD26, is expressed on the surface of immune cells, suggesting that inhibition of DPP‐4 might affect the immune system. The current multicenter observational case–control study was carried out to investigate the effects of DPP‐4 inhibitor (DPP‐4i) administration on Graves' disease (GD) activity. This study comprised patients with GD and type 2 diabetes, who were administered an oral hypoglycemic agent including DPP‐4i. Exacerbation of GD was defined as an increase of antithyroid drug dose by 6 months after oral hypoglycemic agent administration. A total of 80 patients were enrolled and divided into an exacerbation group or a non‐exacerbation group. The frequency of DPP‐4i administration was significantly higher in the exacerbation group (88%) than that in the non‐exacerbation group (31%). In multivariate logistic regression analysis, there was a significant association between DPP‐4i administration and GD exacerbation (odds ratio 7.39). The current study suggests that DPP‐4i administration is associated with GD exacerbation.
■ その他活動・業績